Drug
Bnt326
Bnt326: highest development phase Phase 1/2, developed by BioNTech. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| BNT326 NCT07111520 | Phase 1/2 | Non-small Cell Lung Cancer |
Latest
No recent events.
Follow Bnt326 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.